2023
CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?
Su D, Kluger H, Weiss S. CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma? Annals Of Translational Medicine 2023, 0: 0-0. PMID: 37675335, PMCID: PMC10477634, DOI: 10.21037/atm-23-754.Peer-Reviewed Original Research
2020
19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA
Oria V, Zhang H, Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, Jilaveanu L. 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA. Neuro-Oncology Advances 2020, 2: ii3-ii3. PMCID: PMC7401364, DOI: 10.1093/noajnl/vdaa073.009.Peer-Reviewed Original ResearchMelanoma brain metastasesBrain metastasesTumor growthPI3K/Akt/mTORCell cycle transitionAkt/mTORGrowth of tumorsS cell cycle transitionPhosphorylation of AktMelanoma patientsPoor prognosisNovel drug targetsPatient populationRegulation of PDCD4Metastatic melanomaUnique cohortXenograft modelClinical relevanceNude miceMetastasisCycle transitionMelanomaBrain developmentKey mediatorMelanoma cells
2019
Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma
Kim JM, Weiss S, Sinard JH, Pointdujour-Lim R. Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma. Ocular Oncology And Pathology 2019, 6: 35-38. PMID: 32002403, PMCID: PMC6984155, DOI: 10.1159/000497473.Peer-Reviewed Original Research
2017
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature
Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017, 93: 249-258. PMID: 28746931, PMCID: PMC5617794, DOI: 10.1159/000478050.Peer-Reviewed Original ResearchConceptsMUP patientsProspective melanoma databaseSystemic therapyUnknown primaryMetastatic melanomaClinical trialsSingle-institution studyMKP patientsTreatment guidelinesPoor outcomeMelanoma databaseWorse outcomesTreatment outcomesPatientsBetter outcomesTherapyPatient dataMelanomaGoogle ScholarUnique populationSurvival dataOutcomesLimited dataImmunotherapyTrialsCorrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25)
Weiss SA, Han SW, Lui K, Tchack J, Shapiro R, Berman R, Zhong J, Krogsgaard M, Osman I, Darvishian F. Corrigendum to “Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma” (Hum Pathol 2016;57:116-25). Human Pathology 2017, 63: 222. PMID: 28449825, DOI: 10.1016/j.humpath.2017.03.001.Peer-Reviewed Original Research
2016
Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target.
Weiss S, Martinez C, Vega-Saenz de Miera E, Dolgalev I, Shapiro R, Heguy A, Hernando E, Kirchhoff T, Osman I. Genomic characterization of acral lentiginous melanoma: Identification of altered metabolism as a potential therapeutic target. Journal Of Clinical Oncology 2016, 34: 9524-9524. DOI: 10.1200/jco.2016.34.15_suppl.9524.Peer-Reviewed Original ResearchChapter 20 Management of Melanoma Therapy-Associated Toxicities
Weiss S, Kavecansky J, Pavlick A. Chapter 20 Management of Melanoma Therapy-Associated Toxicities. 2016, 299-319. DOI: 10.1016/b978-0-12-803508-5.00020-2.Peer-Reviewed Original ResearchSkin cancer-related deathsAntitumor immune responseUnique adverse eventsCancer-related deathPatient survival outcomesNew therapeutic strategiesQuality of lifeMelanoma driver mutationsChapter 20 ManagementAdverse eventsAdvanced melanomaSurvival outcomesImmune responseTherapeutic strategiesInitial approvalAggressive natureSkin cancerNew casesPatient safetyDriver mutationsMelanomaSignificant delayTherapyCliniciansVast majority
2015
Role of the Medical Oncologist in the Management of Skin Cancer
Weiss S, Wilson M, Pavlick A. Role of the Medical Oncologist in the Management of Skin Cancer. Current Dermatology Reports 2015, 4: 205-212. DOI: 10.1007/s13671-015-0119-0.Peer-Reviewed Original ResearchMetastatic skin cancerMedical oncologistsCell carcinomaSkin cancerSquamous cell carcinomaMerkel cell carcinomaBasal cell carcinomaSystemic therapyLocal therapyMedical oncologySurgical oncologyField of dermatologyCancerCarcinomaOncologistsRadiation oncologyMedical specialistsOncologyTherapyMulti-disciplinary approachPertinent evidenceSurgeryMelanomaManagementRecurrentTumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas.
Weiss S, Han S, Vogelsang M, Krogsgaard M, Lui K, Shapiro R, Kirchhoff T, Darvishian F, Osman I. Tumor infiltrating lymphocyte (TIL) classifications and association with survival in primary melanomas. Journal Of Clinical Oncology 2015, 33: e20042-e20042. DOI: 10.1200/jco.2015.33.15_suppl.e20042.Peer-Reviewed Original Research